关于 VELOXIS PHARMACEUTICALS, INC.
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Hørsholm, Denmark, with an office in Cary, North Carolina.
Source: Wikipedia
总部2000 Regency Parkway, 27518, Cary, US
成立2016
状态营业中
专利5 项专利
Stabilized tacrolimus compositionUS12403095B2 · 2025
STABILIZED TACROLIMUS COMPOSITIONUS2023101012A1 · 2023
法律信息
| 法定名称 | VELOXIS PHARMACEUTICALS, INC. |
|---|---|
| LEI | 549300YD7MO7TUE8GX79在 GLEIF 上查看 ↗ |
| 注册地址 | 2000 Regency Parkway, 27518, Cary, US |
| 状态 | 营业中 |
来源: GLEIF · 更新于 Oct. 16, 2026